Expression of GR-α and HDAC2 in steroid-Sensitive and steroid-Insensitive interstitial lung disease.

[1]  W. Wuyts,et al.  Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis , 2018, Respirology.

[2]  Y. Kondoh,et al.  Acute and subacute idiopathic interstitial pneumonias , 2016, Respirology.

[3]  Rachel C Chambers,et al.  Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF , 2016, Thorax.

[4]  H. Peh,et al.  Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD , 2016, Chest.

[5]  C. Ruppert,et al.  Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis , 2015, Thorax.

[6]  Yang Zhang,et al.  Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[7]  N. Ambalavanan,et al.  Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice , 2014, European Respiratory Journal.

[8]  W. Funkhouser,et al.  Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. , 2014, Annals of the American Thoracic Society.

[9]  P. Barnes,et al.  Passive Smoking Impairs Histone Deacetylase-2 in Children With Severe Asthma , 2013, Chest.

[10]  E. White,et al.  Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts , 2013, Cell Death and Disease.

[11]  J. Hagood,et al.  Epigenetic regulation of thy-1 by histone deacetylase inhibitor in rat lung fibroblasts. , 2011, American journal of respiratory cell and molecular biology.

[12]  P. Barnes.  Glucocorticosteroids: current and future directions , 2011, British journal of pharmacology.

[13]  P. Barnes,et al.  Nortriptyline Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ , 2011, Journal of Pharmacology and Experimental Therapeutics.

[14]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[15]  I. Adcock,et al.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[16]  G. Chrousos,et al.  The human glucocorticoid receptor: Molecular basis of biologic function , 2010, Steroids.

[17]  I. Adcock,et al.  Glucocorticoid resistance in inflammatory diseases , 2009, The Lancet.

[18]  W. Weichert,et al.  Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.

[19]  S. Romero,et al.  Idiopathic Organizing Pneumonia: A Relapsing Disease , 2007, Respiration.

[20]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[21]  I. Adcock,et al.  Oxidative stress and redox regulation of lung inflammation in COPD , 2006, European Respiratory Journal.

[22]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[23]  J. Cordier.  Cryptogenic organizing pneumonia , 2004, Clinics in chest medicine.

[24]  J. Mullol,et al.  Expression of glucocorticoid receptors α and β in steroid sensitive and steroid insensitive interstitial lung diseases , 2004, Thorax.

[25]  F. Martinez,et al.  Mechanisms of pulmonary fibrosis. , 2004, Annual review of medicine.

[26]  G. Hunninghake,et al.  Idiopathic pulmonary fibrosis. , 2001, The New England journal of medicine.

[27]  R. Strawderman,et al.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. , 2001, The American journal of medicine.

[28]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[29]  P. Herrlich,et al.  Transcriptional cross-talk, the second mode of steroid hormone receptor action , 1998, Journal of Molecular Medicine.

[30]  Y. Nikaido,et al.  Features of idiopathic pulmonary fibrosis with organizing pneumonia. , 1997, Respiration; international review of thoracic diseases.

[31]  A. Cato,et al.  Molecular mechanisms of anti‐inflammatory action of glucocorticoids , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  R. Evans,et al.  Primary structure and expression of a functional human glucocorticoid receptor cDNA , 1985, Nature.